$LUNG

Radhakrishnan Srikanth sold $6K of LUNG

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 3,684 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Original reporting
SEC EDGAR · Radhakrishnan Srikanth
Published Jun 3, 2026, 8:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information (officer selling) but does not introduce new operational/financial guidance or deal/regulatory outcomes.

02

Market read

Traders may briefly reassess sentiment around LUNG, but the event is unlikely to drive a sustained repricing without corroborating fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing does not provide intent, diversification rationale, or whether other insiders sold/bought around the same time.

Relevance 6/10Novelty 6/10Timing: After-hours/filing date (filed June 3) following a June 1 sale

Background

This is an SEC Form 4 insider transaction disclosure for Pulmonx Corp (LUNG).

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

Pulmonx insider Form 4 shows CFO/CSO Radhakrishnan Srikanth sold 3,684 shares in an open-market transaction on June 1.

Expected impact

Likely limited/short-lived impact unless accompanied by unusual volume, guidance changes, or additional insider actions.

Evidence & confidence

The filing is an ownership-change disclosure with a small absolute value (~$5.7k) and no stated link to corporate events; 10b5-1 plan is explicitly marked as not pre-arranged, which can slightly increase interpretive sensitivity but still lacks new company fundamentals.

Market effects

Minimal; insider selling at a single small-cap biotech/device name typically does not reset sector expectations.

None.

None.

Counterpoint

The sale may be routine liquidity/tax-related and not predictive, especially given the small dollar amount.

Key entities

  • Pulmonx Corp

    Company whose insider transaction was reported on SEC Form 4.

  • Radhakrishnan Srikanth

    Chief Science & Technology Officer who sold shares in an open-market transaction.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu